Drug Trial Radar · NCT05701241
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
Last checked: Nov 20, 2026Latest source record: Jun 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Jun 28, 2023
Primary completion
Apr 2029
Study completion Apr 2034
Sponsor
- Lead sponsor
- University Hospital, AntwerpAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Erasmus Medical Center; ZonMw: The Netherlands Organisation for Health Research and Development; Belgium Health Care Knowledge Centre
- First posted
- Jan 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The SAUNA trial is a multi-national, multi-centre, open-label, randomised, controlled, pragmatic clinical trial in patients with advanced, non-functional gastroenteropancreatic (GEP) neuroendocrine tumours (NET) with progressive disease on first-line therapy with somatostatine analogues (SSA). Eligible patients will be divided into two substudies according to the second-line therapy of choice (peptide receptor radionuclide therapy (PRRT) or targeted therapy, at the discretion of the local investigator). Patients within each substudy will be randomised 1:1 between continuation or withdrawal from SSA at the start of second-line systemic therapy. Stratification will occur according to study site and according to the Ki67 value (below 10% (grade 1 and low grade 2) and equal to or above 10% (high grade 2)).
Conditions
- Gastroenteropancreatic Neuroendocrine Tumor
Interventions
Somatostatin analogDrug
Somatostatin analog treatment every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- the difference in progression-free survival (PFS) in patients continuing or stopping second-line therapy with SSAs, as assessed by the blinded local investigator on cross-sectional imaging, according to RECIST 1.1 criteria per substudyTime frame: 18 months after start second-line treatment
- The difference in time to deterioration (TTD) in patients continuing or stopping second-line therapy with SSAs per substudyTime frame: 18 months after start second-line treatment
Locations
19 sites in 2 countries. Site status is shown where the registry gives one.
AZ Monica
Antwerp, Belgium · Not yet recruiting
GZA
Antwerp, Belgium · Active not recruiting
Ziekenhuis Netwerk Antwerpen
Antwerp, Belgium · Withdrawn
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Recruiting
H.U.B.
Brussels, Belgium · Active not recruiting
Antwerp University Hospital
Edegem, Belgium · Recruiting
Centre Hospitalier Universitaire Sart Tilman
Liège, Belgium · Active not recruiting
AZ Klina
Brasschaat, Antwerp, Belgium · Recruiting
AZ Rivierenland
Rumst, Antwerp, Belgium · Active not recruiting
Ghent University Hospital
Ghent, East Flanders, Belgium · Active not recruiting
VITAZ
Sint-Niklaas, East-Flanders, Belgium · Recruiting
University Hospital Leuven
Leuven, Flemish Brabant, Belgium · Recruiting
Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium · Active not recruiting
UMC Groningen
Groningen, Netherlands · Recruiting
Erasmus MC
Rotterdam, Netherlands · Recruiting
Rijnstate
Arnhem, Gelderland, Netherlands · Recruiting
Maastricht UMC+
Maastricht, Limburg, Netherlands · Recruiting
Maxima Medisch Centrum
Eindhoven, North Brabant, Netherlands · Active not recruiting
Amsterdam UMC
Amsterdam, North Holland, Netherlands · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.